Non-Cell Autonomous Effects of the Senescence-Associated Secretory Phenotype in Cancer Therapy
In addition to promoting various forms of cell death, most conventional anti-tumor therapies also promote senescence. There is now extensive evidence that therapy-induced senescence (TIS) might be transient, raising the concern that TIS could represent an undesirable outcome of therapy by providing...
Main Authors: | Tareq Saleh, Liliya Tyutynuk-Massey, Emmanuel K. Cudjoe, Michael O. Idowu, Joseph W. Landry, David A. Gewirtz |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-05-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2018.00164/full |
Similar Items
-
Senolytics for Cancer Therapy: Is All That Glitters Really Gold?
by: Valerie J. Carpenter, et al.
Published: (2021-02-01) -
Studies of Non-Protective Autophagy Provide Evidence that Recovery from Therapy-Induced Senescence is Independent of Early Autophagy
by: Tareq Saleh, et al.
Published: (2020-02-01) -
Cellular Senescence in Arterial Diseases
by: Ippei Shimizu, et al.
Published: (2020-01-01) -
Isolation methodology is essential to the evaluation of the extracellular vesicle component of the senescence‐associated secretory phenotype
by: Ryan Wallis, et al.
Published: (2021-02-01) -
The Emergence of Senescent Surface Biomarkers as Senotherapeutic Targets
by: Martina Rossi, et al.
Published: (2021-07-01)